Aspire Biopharma Holdings, Inc.
ASBP
$0.3655
-$0.0145-3.82%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 427.03% | 696.66% | 363.78% | 8.27% | 159.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 516.97% | 739.45% | 270.38% | 7.31% | 113.10% |
| Operating Income | -516.97% | -739.45% | -270.38% | -7.31% | -113.10% |
| Income Before Tax | -6,801.00% | -867.89% | -270.38% | -7.31% | -113.10% |
| Income Tax Expenses | -- | -100.00% | -- | -- | -- |
| Earnings from Continuing Operations | -6,801.00% | -861.59% | -271.91% | -7.31% | -113.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6,801.00% | -861.59% | -271.91% | -7.31% | -113.10% |
| EBIT | -516.97% | -739.45% | -270.38% | -7.31% | -113.10% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4,908.33% | -750.00% | -- | -- | -- |
| Normalized Basic EPS | -475.00% | -900.00% | -- | -- | -- |
| EPS Diluted | -4,908.33% | -750.00% | -- | -- | -- |
| Normalized Diluted EPS | -475.00% | -900.00% | -- | -- | -- |
| Average Basic Shares Outstanding | 37.29% | -0.68% | -- | -- | -- |
| Average Diluted Shares Outstanding | 37.29% | -0.68% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |